China SXT Pharmaceuticals, Inc. - Class A (SXTC) share price
China SXT Pharmaceuticals, Inc. - Class A (NASDAQ:SXTC) last traded at $2.83, down 3.41% on the day (quote 2026-11-06 21:00 UTC), with a market cap of $0.00B and a 52-week range of $2.71 to $8,376,000.
| Exchange | NASDAQ |
|---|---|
| Currency | USD |
| Last price | $2.83 |
| 1-day move | -3.41% |
| 52-week range | $2.71 - $8,376,000 |
| Market cap | $0.00B |
| From 52-week high | -100.00% |
| Volume vs average | 0.2x |
| Falling Shares risk score | 44/100 (ELEVATED) |
| Country | United States |
Frequently asked questions
Why is China SXT Pharmaceuticals, Inc. - Class A falling today?
China SXT Pharmaceuticals, Inc. - Class A (NASDAQ:SXTC) is down 3.41% at its latest quote and trades 100.0% below its 52-week high. A price fall alone does not identify a cause: Falling Shares Intelligence links a move to a filing, order or news item only when a source supports it.
What is the China SXT Pharmaceuticals, Inc. - Class A share price today?
China SXT Pharmaceuticals, Inc. - Class A (NASDAQ:SXTC) last traded at $2.83, a -3.41% move on the day as of 2026-11-06 21:00 UTC. Market data comes from public feeds and may be delayed; it is not investment advice.
What is the 52-week range of China SXT Pharmaceuticals, Inc. - Class A?
China SXT Pharmaceuticals, Inc. - Class A's 52-week low is $2.71 and its 52-week high is $8,376,000; the shares trade 100.0% below the high.
What is the market cap of China SXT Pharmaceuticals, Inc. - Class A?
China SXT Pharmaceuticals, Inc. - Class A has a market capitalisation of about $0.00B at the latest price.
What are the risks of investing in China SXT Pharmaceuticals, Inc. - Class A?
Falling Shares Intelligence rates China SXT Pharmaceuticals, Inc. - Class A 44/100 (ELEVATED) on price stress, volume and disclosure signals. Risk scores are analytical indicators, not allegations or investment advice. Review exchange filings and the company's own disclosures before any decision.
Data is compiled from public exchange feeds and may be delayed. Not investment advice.
Wung Thomas, Editor-in-Chief: wungthomas@fallingshares.com. General enquiries and corrections: info@fallingshares.com